We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Message Testing for Tobacco-Related Corrective Statements

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01282008
First Posted: January 24, 2011
Last Update Posted: October 6, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
  Purpose

BACKGROUND:

This document outlines the study design and procedures to be used to evaluate a series of corrective statements to augment consumer knowledge and beliefs about smoking as related to past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions resultant of past marketing and promotion practices undertaken by the tobacco industry.

OBJECTIVES:

The U.S. Department of Justice has asked NCI to take the lead on developing and testing corrective statements with adult and youth audiences to ensure both message comprehension and avoidance of unintended consequences of message exposure, such as boomerang effects, smoking triggers, or knowledge gaps.

The court has identified five areas that the statements shall address:

  1. The adverse health effects of smoking;
  2. The addictiveness of smoking and nicotine;
  3. The lack of any significant health benefit from smoking low tar, light, ultra light, mild, and natural cigarettes;
  4. The tobacco industry s manipulation of cigarette design and composition to ensure optimum nicotine delivery;
  5. The adverse health effects of secondhand smoke.

ELIGIBILITY:

Message testing will be undertaken with the following audiences:

  • Current smokers (with an oversample of low socioeconomic status individuals)
  • General population nonsmokers and former smokers (with an oversample of low socioeconomic status individuals)
  • Spanish-speaking Hispanics
  • Youth age 14-17

DESIGN:

Both qualitative and quantitative methods (focus groups and post-test comparison group Web-enabled surveys) will be used to develop and test a range of corrective statements in the five areas outlined by the court.

  • Focus group participants: 48-64
  • Survey participants: 2500

Condition
Tobacco Smoking Communication

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Message Testing for Tobacco-Related Corrective Statements

Further study details as provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):

Primary Outcome Measures:
  • Knowledge [ Time Frame: Immediately upon exposure to stimuli ]

Estimated Enrollment: 627
Study Start Date: January 10, 2011
Detailed Description:

BACKGROUND:

This document outlines the study design and procedures to be used to evaluate a series of corrective statements to augment consumer knowledge and beliefs about smoking as related to past actions of tobacco companies. The statements were ordered by a U.S. Federal Court in U.S. v. Philip Morris USA, Inc., and are intended to target potential misperceptions resultant of past marketing and promotion practices undertaken by the tobacco industry.

OBJECTIVES:

The U.S. Department of Justice has asked NCI to take the lead on developing and testing corrective statements with adult and youth audiences to ensure both message comprehension and avoidance of unintended consequences of message exposure, such as boomerang effects, smoking triggers, or knowledge gaps.

The court has identified five areas that the statements shall address:

  1. The adverse health effects of smoking;
  2. The addictiveness of smoking and nicotine;
  3. The lack of any significant health benefit from smoking low tar, light, ultra light, mild, and natural cigarettes;
  4. The tobacco industry s manipulation of cigarette design and composition to ensure optimum nicotine delivery;
  5. The adverse health effects of secondhand smoke.

ELIGIBILITY:

Message testing will be undertaken with the following audiences:

  • Current smokers (with an oversample of low socioeconomic status individuals)
  • General population nonsmokers and former smokers (with an oversample of low socioeconomic status individuals)
  • Spanish-speaking Hispanics
  • Youth age 14-17

DESIGN:

Both qualitative and quantitative methods (focus groups and post-test comparison group Web-enabled surveys) will be used to develop and test a range of corrective statements in the five areas outlined by the court.

  • Focus group participants: 48-64
  • Survey participants: 2500
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:
  • Youth age 14-17
  • Youth current smokers, former smokers, and never smokers
  • Youth male and female genders
  • Youth of all race/ethnicity categories, including: White, Black/African American, Asian, Hispanic/Latino, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander

EXCLUSION CRITERIA:

Participants will be excluded from focus groups and survey if they work in:

  • Media
  • Advertising, market research
  • Public health or health promotion
  • An employee of the Federal Govemment who works at HHS or DoJ
  • The tobacco or alcohol industries
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01282008


Locations
United States, Maryland
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Kelly D Blake, D.Sc. National Cancer Institute (NCI)
  More Information

Publications:
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01282008     History of Changes
Other Study ID Numbers: 999911067
11-C-N067
First Submitted: January 21, 2011
First Posted: January 24, 2011
Last Update Posted: October 6, 2017
Last Verified: January 25, 2017

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Online Surveys
Tobacco Corrective Statements
Message Testing
Focus Groups